{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T15:02:41Z","timestamp":1725375761805},"reference-count":28,"publisher":"SAGE Publications","issue":"S1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cutan Med Surg"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1007\/s10227-006-0101-3","type":"journal-article","created":{"date-parts":[[2006,4,21]],"date-time":"2006-04-21T21:57:00Z","timestamp":1145656620000},"page":"4-9","source":"Crossref","is-referenced-by-count":5,"title":["Efalizumab, a reversible T-cell modulator for psoriasis"],"prefix":"10.1177","volume":"9","author":[{"given":"Neil H.","family":"Shear","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard G.","family":"Langley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2006,4,20]]},"reference":[{"key":"101_CR1","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1172\/JCI200422147","volume":"113","author":"BJ Nickoloff","year":"2004","unstructured":"Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004; 113:1664\u20131675","journal-title":"J Clin Invest"},{"key":"101_CR2","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1046\/j.1365-2133.1998.02511.x","volume":"139","author":"MA Gupta","year":"1998","unstructured":"Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998; 139:846\u2013850","journal-title":"Br J Dermatol"},{"key":"101_CR3","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1503\/cmaj.1031335","volume":"170","author":"SRA Walsh","year":"2004","unstructured":"Walsh SRA, Shear NH. Psoriasis and the new biologic agents: interrupting a T-AP dance. CMAJ 2004; 170:1933\u20131941","journal-title":"CMAJ"},{"key":"101_CR4","doi-asserted-by":"crossref","unstructured":"Langley RG, Ho V, Lynde C, et al. Recommendations for incorporating biologicals into management of moderate-to-severe plaque psoriasis: individualized patient approaches. J Cutan Med Surg 2005; This supplement","DOI":"10.1007\/s10227-006-0103-1"},{"key":"101_CR5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clim.2004.06.001","volume":"113","author":"Y Vugmeyster","year":"2004","unstructured":"Vugmeyster Y, Kikuchi T, Lowes MA, et al. Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8 + T cells into lesional skin. Clin Immunol 2004; 113:38\u201346","journal-title":"Clin Immunol"},{"key":"101_CR6","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1124\/dmd.104.002584","volume":"33","author":"GP Coffey","year":"2005","unstructured":"Coffey GP, Fox JA, Pippig S, et al. Tissue distribution and receptor-mediated clearance of anti-CD11a antibody in mice. Drug Metab Dispos 2005; 33:623\u2013629","journal-title":"Drug Metab Dispos"},{"key":"101_CR7","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.4049\/jimmunol.157.5.1973","volume":"157","author":"DO Willenborg","year":"1996","unstructured":"Willenborg DO, Staykova MA, Miyasaka M. Short term treatment with soluble neuroantigen and anti-CD11a (LFA-1) protects rats against autoimmune encephalomyelitis: treatment abrogates autoimmune disease but not autoimmunity. J Immunol 1996; 157:1973\u20131980","journal-title":"J Immunol"},{"key":"101_CR8","unstructured":"Papp K. Patient management in psoriasis treatment using efalizumab. J Cutan Med Surg 2005; This supplement"},{"key":"101_CR9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1159\/000077660","volume":"208","author":"D Jullien","year":"2004","unstructured":"Jullien D, Prinz JC, Langley RG, et al. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action. Dermatology 2004; 208:297\u2013306","journal-title":"Dermatology"},{"key":"101_CR10","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1034\/j.1600-0625.2002.110410.x","volume":"11","author":"JM Ovigne","year":"2002","unstructured":"Ovigne JM, Baker BS, Davison SC, et al. Epidermal CD8 + T cells reactive with group A streptococcal antigens in chronic plaque psoriasis. Exp Dermatol 2002; 11:357\u2013364","journal-title":"Exp Dermatol"},{"key":"101_CR11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0002-9440(10)65109-7","volume":"155","author":"BJ Nickoloff","year":"1999","unstructured":"Nickoloff BJ, Wrone-Smith T. Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. Am J Pathol 1999; 155:145\u2013158","journal-title":"Am J Pathol"},{"key":"101_CR12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1046\/j.1468-3083.2003.00720.x","volume":"17","author":"JC Prinz","year":"2003","unstructured":"Prinz JC. The role of T cells in psoriasis. J Eur Acad Dermatol Venereol 2003; 17:257\u2013270","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"101_CR13","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0196-9781(03)00083-4","volume":"24","author":"ME Anderson","year":"2003","unstructured":"Anderson ME, Siahaan TJ. Targeting ICAM-1\/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors. Peptides 2003; 24:487\u2013501","journal-title":"Peptides"},{"key":"101_CR14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.4049\/jimmunol.160.1.467","volume":"160","author":"XZ Shang","year":"1998","unstructured":"Shang XZ, Lang BJ, Issekutz AC. Adhesion molecule mechanisms mediating monocyte migration through synovial fibroblast and endothelium barriers: role for CD11\/CD18, very late antigen-4 (CD49d\/CD29), very late antigen-5 (CD49e\/CD29), and vascular cell adhesion molecule-1 (CD106). J Immunol 1998; 160:467\u2013474","journal-title":"J Immunol"},{"key":"101_CR15","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/archderm.138.5.591","volume":"138","author":"AB Gottlieb","year":"2002","unstructured":"Gottlieb AB, Krueger JG, Wittkowski K, et al. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002; 138:591\u2013600","journal-title":"Arch Dermatol"},{"key":"101_CR16","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1177\/0091270004270260","volume":"45","author":"DL Mortensen","year":"2005","unstructured":"Mortensen DL, Walicke PA, Wang X, et al. Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis. J Clin Pharmacol 2005; 45:286\u2013298","journal-title":"J Clin Pharmacol"},{"key":"101_CR17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00403-002-0334-y","volume":"294","author":"M Deguchi","year":"2002","unstructured":"Deguchi M, Aiba S, Ohtani H, et al. Comparison of the distribution and numbers of antigen-presenting cells among T-lymphocyte-mediated dermatoses: CD1a +, Factor XIIIa +, and CD68 + cells in eczematous dermatitis, psoriasis, lichen planus and graft-versus-host disease. Arch Dermatol Res 2002; 294:297\u2013302","journal-title":"Arch Dermatol Res"},{"key":"101_CR18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0167-5699(98)01381-4","volume":"20","author":"JD Bos","year":"1999","unstructured":"Bos JD, De Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today 1999; 20:40\u201346","journal-title":"Immunol Today"},{"key":"101_CR19","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/1523-1747.ep12472106","volume":"100","author":"I Bruynzeel","year":"1993","unstructured":"Bruynzeel I, Koopman G, van der Raaij LM, et al. CD44 antibody stimulates adhesion of peripheral blood T cells to keratinocytes through the leukocyte function-associated antigen-1\/intercellular adhesion molecule-1 pathway. J Invest Dermatol 1993; 100:424\u2013428","journal-title":"J Invest Dermatol"},{"key":"101_CR20","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.4049\/jimmunol.157.11.4986","volume":"157","author":"WA Werther","year":"1996","unstructured":"Werther WA, Gonzalez TN, O\u2019Connor SJ, McCabe S, Chan B, Hotaling T, Champe M, Fox JA, Jardieu PM, Berman PW, Presta LG. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 1996; 157:4986\u20134965","journal-title":"J Immunol"},{"issue":"Suppl 2","key":"101_CR21","first-page":"ii30","volume":"64","author":"JG Krueger","year":"2005","unstructured":"Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005; 64 Suppl 2:ii30\u201336","journal-title":"Ann Rheum Dis"},{"key":"101_CR22","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1124\/jpet.104.067611","volume":"310","author":"GP Coffey","year":"2004","unstructured":"Coffey GP, Stefanich E, Palmieri S, et al. In vitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells. J Pharmacol Exp Ther 2004; 310:896\u2013904","journal-title":"J Pharmacol Exp Ther"},{"key":"101_CR23","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1177\/0091270004272731","volume":"45","author":"YN Sun","year":"2005","unstructured":"Sun YN, Lu JF, Joshi A, et al. Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects. J Clin Pharmacol 2005; 45:468\u2013476","journal-title":"J Clin Pharmacol"},{"key":"101_CR24","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1023\/A:1020917122093","volume":"27","author":"RJ Bauer","year":"1999","unstructured":"Bauer RJ, Dedrick RL, White ML, et al. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm 1999; 27:397\u2013420","journal-title":"J Pharmacokinet Biopharm"},{"key":"101_CR25","unstructured":"Raptiva\u00ae (efalizumab) US Prescribing Information. Genentech, Inc. 2005"},{"key":"101_CR26","unstructured":"Raptiva\u00ae (efalizumab) Canadian Prescribing Information. Serono Canada, Inc. 2005"},{"key":"101_CR27","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2165\/00128071-200506020-00006","volume":"6","author":"K Wellington","year":"2005","unstructured":"Wellington K, Perry CM. Efalizumab. Am J Clin Dermatol 2005; 6:113\u2013118","journal-title":"Am J Clin Dermatol"},{"key":"101_CR28","unstructured":"Poulin Y, Papp KA, Carey W, Gulliver W. Efalizumab for long-term control of moderate-to-severe psoriasis. J Cutan Med Surg 2005; This supplement"}],"container-title":["Journal of Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1007\/s10227-006-0101-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T04:54:30Z","timestamp":1683435270000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10227-006-0101-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":28,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["101"],"URL":"https:\/\/doi.org\/10.1007\/s10227-006-0101-3","relation":{},"ISSN":["1203-4754","1615-7109"],"issn-type":[{"value":"1203-4754","type":"print"},{"value":"1615-7109","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12]]}}}